carteolol has been researched along with Glaucoma in 39 studies
Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Systemic effects of two topical B adrenergic blocking agents, carteolol and metipranolol, recently introduced in the treatment of open angle chronic glaucoma, were investigated in two groups of 10 asthmatic patients, according to a controlled trial device." | 9.06 | [Comparison of the effects of carteolol and metipranolol eyedrops on the ventilatory and cardiovascular functions in asthmatics]. ( Dufier, JL; Hugues, FC; Le Jeunne, C; Munera, Y, 1987) |
| "In patients with normal-tension glaucoma (NTG), topical dorzolamide might enhance the vessel density (VD), topical carteolol decreased the VD in the inferior-temporal peripapillary retina, whereas topical brimonidine did not change the VD." | 8.02 | Optical Coherence Tomography Angiography Vessel Density Changes in Normal-tension Glaucoma Treated With Carteolol, Brimonidine, or Dorzolamide. ( Chen, LC; Chuang, LH; Huang, SM; Lin, YH; Su, WW, 2021) |
| "The purpose of the study was to evaluate influence of betaxolol, brimonidine and carteolol in the progression of the visual field defects during time at patients with normotensive glaucoma (NTG)." | 7.96 | Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma. ( Fůs, M; Lešták, J; Marešová, K; Weissová, I, 2020) |
| "The therapeutic effects of carteolol hydrochloride were evaluated in the treatment of 44 uveitis patients (51 eyes) with intraocular pressure elevation or secondary glaucoma." | 7.67 | Hypotensive effect of carteolol on intraocular pressure elevation and secondary glaucoma associated with endogenous uveitis. ( Ichiishi, A; Matsuda, H; Ohno, S, 1989) |
| "Carteolol is a nonselective beta-blocker with intrinsic sympathomimetic activity (I." | 6.67 | A long term clinical trial of carteolol in the management of glaucoma. Belgian Carteolol Study Participants. ( Goethals, M; Missotten, L; Vandeputte, O; Vercruysse, K, 1992) |
| "Carteolol is a nonselective adrenergic blocking agent." | 5.31 | Color Doppler imaging of retrobulbar hemodynamics after topical carteolol in normal tension glaucoma. ( Chen, MJ; Ching, J; Chiou, HJ; Chou, K; Hsu, WM, 2001) |
| "Systemic effects of two topical B adrenergic blocking agents, carteolol and metipranolol, recently introduced in the treatment of open angle chronic glaucoma, were investigated in two groups of 10 asthmatic patients, according to a controlled trial device." | 5.06 | [Comparison of the effects of carteolol and metipranolol eyedrops on the ventilatory and cardiovascular functions in asthmatics]. ( Dufier, JL; Hugues, FC; Le Jeunne, C; Munera, Y, 1987) |
| " Its effect on intraocular pressure and heart rate was tested in a comparison with timolol maleate, as was subjective tolerance of it, in 28 eyes (14 subjects) with either ocular hypertension or simple chronic open-angle glaucoma." | 5.06 | [Tolerance and pharmacologic effectiveness of antiglaucoma eyedrops]. ( Flury, H; Martenet, AC; Tournoux, A, 1986) |
| " Ophthalmic carteolol eye drops are nonselective beta-blockers and effective against glaucoma and ocular hypertension." | 4.31 | Life-threatening Vasospastic Angina Induced by Carteolol Eye Drops. ( Akashi, R; Eto, R; Ikeda, S; Kawano, H; Maemura, K; Suzuki, A, 2023) |
| "To investigate the treatment persistence of carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution (CAR/LAT) and other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions (BB/FP) in the treatment of glaucoma." | 4.31 | Persistence of the carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution, compared with the other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions. ( Kashiwagi, K; Ouchi, K; Shibasaki, Y; Suginaka, M, 2023) |
| "In patients with normal-tension glaucoma (NTG), topical dorzolamide might enhance the vessel density (VD), topical carteolol decreased the VD in the inferior-temporal peripapillary retina, whereas topical brimonidine did not change the VD." | 4.02 | Optical Coherence Tomography Angiography Vessel Density Changes in Normal-tension Glaucoma Treated With Carteolol, Brimonidine, or Dorzolamide. ( Chen, LC; Chuang, LH; Huang, SM; Lin, YH; Su, WW, 2021) |
| "The purpose of the study was to evaluate influence of betaxolol, brimonidine and carteolol in the progression of the visual field defects during time at patients with normotensive glaucoma (NTG)." | 3.96 | Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma. ( Fůs, M; Lešták, J; Marešová, K; Weissová, I, 2020) |
| "To assess the potential of chitosan (CS) nanoparticles for ocular drug delivery by investigating their intraocular retention by γ-scintigraphy and intraocular pressure reduction." | 3.80 | Chitosan nanoparticles amplify the ocular hypotensive effect of cateolol in rabbits. ( Ali, A; Ali, J; Bhatnagar, A; Kumar, N, 2014) |
| " These dendrimers react with the neutral form of carteolol (an ocular anti-hypertensive drug used to treat glaucoma) to afford ion pair (saline) species." | 3.76 | Designing dendrimers for ocular drug delivery. ( Caminade, AM; Duhayon, C; Elena, PP; Majoral, JP; Malecaze, F; Soler, V; Spataro, G; Turrin, CO, 2010) |
| "In this study, the various antiglaucoma drugs including betaxolol, timolol, levobunolol, carteolol, brimonidine, dipivefrin, dorzolamide, brinzolamide, latanoprost, unoprostone, and pilocarpine were used to investigate the effects of cellular cytotoxicity in cultured bovine corneal endothelial cells." | 3.74 | Cellular cytotoxicity of antiglaucoma drugs in cultured corneal endothelial cells. ( Hong, SJ; Wang, HZ; Wu, KY, 2007) |
| " In the present study, we investigated various commercial antiglaucoma drugs including timolol (0." | 3.72 | Effects of commercial antiglaucoma drugs to glutamate-induced [Ca2+)]i increase in cultured neuroblastoma cells. ( Fong, JC; Hong, SJ; Wang, HZ; Wu, KY, 2003) |
| "Carteolol is a nonselective beta-blocker with intrinsic sympathomimetic activity (I." | 2.67 | A long term clinical trial of carteolol in the management of glaucoma. Belgian Carteolol Study Participants. ( Goethals, M; Missotten, L; Vandeputte, O; Vercruysse, K, 1992) |
| "The carteolol was solved in saline containing additives (0." | 1.48 | Enhancement in Corneal Permeability of Dissolved Carteolol by Its Combination with Magnesium Hydroxide Nanoparticles. ( Fukuoka, Y; Ishii, M; Kanai, K; Nagai, N; Okamoto, N; Otake, H; Shimomura, Y; Yamaoka, S, 2018) |
| "Betaxolol was twice as effective at preventing the effect of IgG (34% to 37%) than that of zymosan (14%), regardless of the presence of BAK." | 1.32 | In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system. ( Baudouin, C; Blondin, C; Cholley, B; Haeffner-Cavaillon, N; Hamard, P, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (25.64) | 18.7374 |
| 1990's | 8 (20.51) | 18.2507 |
| 2000's | 10 (25.64) | 29.6817 |
| 2010's | 7 (17.95) | 24.3611 |
| 2020's | 4 (10.26) | 2.80 |
| Authors | Studies |
|---|---|
| Eto, R | 2 |
| Kawano, H | 2 |
| Suzuki, A | 2 |
| Akashi, R | 2 |
| Ikeda, S | 2 |
| Maemura, K | 2 |
| Kashiwagi, K | 1 |
| Ouchi, K | 1 |
| Shibasaki, Y | 1 |
| Suginaka, M | 1 |
| Lešták, J | 1 |
| Fůs, M | 1 |
| Weissová, I | 1 |
| Marešová, K | 1 |
| Lin, YH | 1 |
| Su, WW | 1 |
| Huang, SM | 1 |
| Chuang, LH | 1 |
| Chen, LC | 1 |
| Nagai, N | 1 |
| Yamaoka, S | 1 |
| Fukuoka, Y | 1 |
| Ishii, M | 1 |
| Otake, H | 1 |
| Kanai, K | 1 |
| Okamoto, N | 1 |
| Shimomura, Y | 1 |
| Soares, RR | 1 |
| Razeghinejad, MR | 1 |
| Chikama, T | 1 |
| Araie, M | 2 |
| Nishida, T | 1 |
| Ali, J | 1 |
| Bhatnagar, A | 1 |
| Kumar, N | 1 |
| Ali, A | 1 |
| Shapiro, MK | 1 |
| Gorn, R | 1 |
| Spataro, G | 1 |
| Malecaze, F | 1 |
| Turrin, CO | 1 |
| Soler, V | 1 |
| Duhayon, C | 1 |
| Elena, PP | 1 |
| Majoral, JP | 1 |
| Caminade, AM | 1 |
| Machů, V | 1 |
| Kawai, K | 1 |
| Ohashi, H | 1 |
| Suzuki, T | 1 |
| Kitagaki, H | 1 |
| Fujisawa, S | 1 |
| Hong, SJ | 3 |
| Wu, KY | 3 |
| Wang, HZ | 3 |
| Fong, JC | 1 |
| Blondin, C | 1 |
| Hamard, P | 1 |
| Cholley, B | 1 |
| Haeffner-Cavaillon, N | 1 |
| Baudouin, C | 2 |
| Ignat, F | 1 |
| Hino, K | 1 |
| Mori, K | 1 |
| Sotozono, C | 1 |
| Ikeda, Y | 1 |
| Naruse, S | 1 |
| Ishibashi, T | 1 |
| Nanjo, Y | 1 |
| Kinoshita, S | 1 |
| Malvitte, L | 1 |
| Montange, T | 1 |
| Vejux, A | 1 |
| Bron, AM | 1 |
| Creuzot-Garcher, C | 1 |
| Lizard, G | 1 |
| Henness, S | 1 |
| Swainston Harrison, T | 1 |
| Keating, GM | 1 |
| Ravet, O | 1 |
| Negishi, C | 2 |
| Ueda, S | 1 |
| Kanai, A | 2 |
| Nakajima, A | 2 |
| Funahashi, M | 1 |
| Kitazawa, Y | 2 |
| Komemushi, S | 1 |
| Uesugi, Y | 1 |
| Zimmerman, TJ | 1 |
| Frishman, WH | 1 |
| Fuksbrumer, MS | 1 |
| Tannenbaum, M | 1 |
| Koseki, N | 1 |
| Shirato, S | 1 |
| Yamagami, J | 1 |
| Giordano-Labadie, F | 2 |
| Lepoittevin, JP | 1 |
| Calix, I | 1 |
| Bazex, J | 2 |
| Carrière, M | 1 |
| Schwarze, HP | 1 |
| Loche, F | 1 |
| Nino, M | 1 |
| Suppa, F | 1 |
| Ayala, F | 1 |
| Balato, N | 1 |
| Chen, MJ | 1 |
| Ching, J | 1 |
| Chou, K | 1 |
| Chiou, HJ | 1 |
| Hsu, WM | 1 |
| Vercruysse, K | 1 |
| Goethals, M | 1 |
| Vandeputte, O | 1 |
| Missotten, L | 1 |
| James, IM | 1 |
| Pillunat, LE | 1 |
| Stodtmeister, R | 1 |
| Ohno, S | 1 |
| Ichiishi, A | 1 |
| Matsuda, H | 1 |
| Hugues, FC | 1 |
| Le Jeunne, C | 1 |
| Munera, Y | 1 |
| Dufier, JL | 1 |
| Schnarr, KD | 1 |
| Duff, GR | 1 |
| Newcombe, RG | 1 |
| Flury, H | 1 |
| Tournoux, A | 1 |
| Martenet, AC | 1 |
5 reviews available for carteolol and Glaucoma
| Article | Year |
|---|---|
Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Carteolol; Clinical Trials as Topic; Glaucoma; Humans; Instillati | 2007 |
[The deleterious effect of certain surface active agents on the ocular surface].
Topics: Administration, Topical; Antihypertensive Agents; Carteolol; Epithelium, Corneal; Glaucoma; Humans; | 2007 |
Topical ophthalmic beta blockers: a comparative review.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Animals; Betaxolol; Carteolol; Drug Tolerance; | 1993 |
Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Betaxolol; Carteolol; Glaucoma; Humans; Levobu | 1994 |
Pharmacologic effects of beta-blocking agents used in the management of glaucoma.
Topics: Adrenergic beta-Antagonists; Betaxolol; Carteolol; Glaucoma; Heart Rate; Humans; Intraocular Pressur | 1989 |
7 trials available for carteolol and Glaucoma
| Article | Year |
|---|---|
[Influence on ocular surface and intraocular pressure of switching from preservative-containing to preservative-free carteolol hydrochloride ophthalmic solution].
Topics: Aged; Aged, 80 and over; Carteolol; Corneal Diseases; Female; Glaucoma; Humans; Intraocular Pressure | 2013 |
[Effects of beta-blocking agent carteolol on healthy volunteers and glaucoma patients (author's transl)].
Topics: Adrenergic beta-Antagonists; Adult; Carteolol; Clinical Trials as Topic; Dose-Response Relationship, | 1981 |
[Effect of non-surgical ocular hypotensive therapy in normal-tension glaucoma].
Topics: Carteolol; Drug Therapy, Combination; Epinephrine; Glaucoma; Humans; Intraocular Pressure; Middle Ag | 1997 |
A long term clinical trial of carteolol in the management of glaucoma. Belgian Carteolol Study Participants.
Topics: Adult; Aged; Carteolol; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Visual Fi | 1992 |
[Comparison of the effects of carteolol and metipranolol eyedrops on the ventilatory and cardiovascular functions in asthmatics].
Topics: Adult; Asthma; Blood Pressure; Carteolol; Clinical Trials as Topic; Female; Glaucoma; Heart; Heart R | 1987 |
The 12-hour control of intraocular pressure on carteolol 2% twice daily.
Topics: Aged; Aged, 80 and over; Carteolol; Clinical Trials as Topic; Double-Blind Method; Female; Glaucoma; | 1988 |
[Tolerance and pharmacologic effectiveness of antiglaucoma eyedrops].
Topics: Adult; Aged; Carteolol; Double-Blind Method; Female; Glaucoma; Glaucoma, Open-Angle; Heart Rate; Hum | 1986 |
27 other studies available for carteolol and Glaucoma
| Article | Year |
|---|---|
Life-threatening Vasospastic Angina Induced by Carteolol Eye Drops.
Topics: Adrenergic beta-Antagonists; Angina Pectoris, Variant; Carteolol; Coronary Vasospasm; Glaucoma; Huma | 2023 |
Life-threatening Vasospastic Angina Induced by Carteolol Eye Drops.
Topics: Adrenergic beta-Antagonists; Angina Pectoris, Variant; Carteolol; Coronary Vasospasm; Glaucoma; Huma | 2023 |
Life-threatening Vasospastic Angina Induced by Carteolol Eye Drops.
Topics: Adrenergic beta-Antagonists; Angina Pectoris, Variant; Carteolol; Coronary Vasospasm; Glaucoma; Huma | 2023 |
Life-threatening Vasospastic Angina Induced by Carteolol Eye Drops.
Topics: Adrenergic beta-Antagonists; Angina Pectoris, Variant; Carteolol; Coronary Vasospasm; Glaucoma; Huma | 2023 |
Persistence of the carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution, compared with the other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions.
Topics: Antihypertensive Agents; Carteolol; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Ocular Hype | 2023 |
Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma.
Topics: Betaxolol; Carteolol; Evoked Potentials, Visual; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular | 2020 |
Optical Coherence Tomography Angiography Vessel Density Changes in Normal-tension Glaucoma Treated With Carteolol, Brimonidine, or Dorzolamide.
Topics: Angiography; Brimonidine Tartrate; Carteolol; Female; Fluorescein Angiography; Glaucoma; Glaucoma, O | 2021 |
Enhancement in Corneal Permeability of Dissolved Carteolol by Its Combination with Magnesium Hydroxide Nanoparticles.
Topics: Adrenergic beta-Antagonists; Animals; Carteolol; Cornea; Dose-Response Relationship, Drug; Glaucoma; | 2018 |
Efficacy of the combination of carteolol hydrochloride + latanoprost in the treatment of glaucoma and ocular hypertension.
Topics: Antihypertensive Agents; Carteolol; Drug Therapy, Combination; Female; Glaucoma; Humans; Latanoprost | 2018 |
Chitosan nanoparticles amplify the ocular hypotensive effect of cateolol in rabbits.
Topics: Adhesiveness; Animals; Carteolol; Chitosan; Cornea; Drug Carriers; Glaucoma; Hydroquinones; Intraocu | 2014 |
The possible treatment of migraine with carteolol hydrochloride.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Carteolol; Female; Glaucoma; Humans; Middle Ag | 1999 |
Designing dendrimers for ocular drug delivery.
Topics: Animals; Carboxylic Acids; Carteolol; Dendrimers; Drug Administration Schedule; Drug Carriers; Drug | 2010 |
[The influence of carteolol and pentoxyphylin on the visual field in glaucoma patients--case reports of selected patients].
Topics: Aged; Carteolol; Female; Glaucoma; Humans; Male; Middle Aged; Pentoxifylline; Visual Fields | 2010 |
[Effect of anti-glaucoma drugs on inflammatory cytokine production by human and murine peripheral blood mononuclear cells].
Topics: Adrenergic beta-Antagonists; Adult; Animals; Carteolol; Cells, Cultured; Enzyme-Linked Immunosorbent | 2010 |
Effects of commercial antiglaucoma drugs to glutamate-induced [Ca2+)]i increase in cultured neuroblastoma cells.
Topics: Animals; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Calcium; Carteolol; Cell Death; D | 2003 |
In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system.
Topics: Adrenergic beta-Antagonists; Benzalkonium Compounds; Betaxolol; Carteolol; Complement System Protein | 2003 |
[Neuroprotection and vasoprotection in glaucoma].
Topics: Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Carteolol; Drug Therapy, Combination; Glau | 2004 |
[A case of severe glaucoma with pseudopemphigoid successfully treated by filtration surgery using amniotic membrane].
Topics: Aged, 80 and over; Amnion; Carteolol; Filtering Surgery; Glaucoma; Humans; Male; Pemphigoid, Bullous | 2006 |
Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs.
Topics: Administration, Topical; Aged; Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; C | 2007 |
Cellular cytotoxicity of antiglaucoma drugs in cultured corneal endothelial cells.
Topics: Animals; Betaxolol; Carteolol; Cattle; Cells, Cultured; Dose-Response Relationship, Drug; Endothelia | 2007 |
[Studies on the treatment of glaucomatous eyes with carteolol ophthalmic solution (author's transl)].
Topics: Adult; Aged; Carteolol; Female; Glaucoma; Humans; Male; Middle Aged; Ophthalmic Solutions; Propanola | 1981 |
Effects of pilocarpine and other antiglaucoma drugs on cultured human Tenon's fibroblast cells.
Topics: Adrenergic beta-Antagonists; Betaxolol; Carteolol; Cell Division; Cells, Cultured; Eye; Fibroblasts; | 1997 |
[Contact allergy to beta blockaders in eye drops: cross allergy?].
Topics: Adrenergic beta-Antagonists; Aged; Carteolol; Cross Reactions; Dermatitis, Contact; Eyelid Diseases; | 1997 |
Difficulties in the interpretation of patch test reactions to ophthalmic beta-blockers.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Aged; Carteolol; Conjunctivitis, Allergic; Der | 1998 |
Allergic contact dermatitis due to the beta-blocker befunolol in eyedrops, with cross-sensitivity to carteolol.
Topics: Adrenergic beta-Antagonists; Aged; Carteolol; Dermatitis, Allergic Contact; Female; Glaucoma; Humans | 2001 |
Color Doppler imaging of retrobulbar hemodynamics after topical carteolol in normal tension glaucoma.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Aged; Carteolol; Female; Glaucoma; Hemodynamic | 2001 |
Pressure compliance test of the optic nerve head: influence of different antiglaucoma drugs.
Topics: Acetazolamide; Adrenergic beta-Antagonists; Betaxolol; Carteolol; Glaucoma; Glaucoma, Open-Angle; Hu | 1989 |
Hypotensive effect of carteolol on intraocular pressure elevation and secondary glaucoma associated with endogenous uveitis.
Topics: Adolescent; Adult; Aged; Blood Pressure; Carteolol; Child; Drug Administration Schedule; Female; Gla | 1989 |
New topical beta-blockers for glaucoma.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Betaxolol; Carteolol; Glaucoma; Humans; Metipr | 1987 |
[Comparative multicenter study of carteolol eyedrops with other beta blockers in 768 patients under normal conditions].
Topics: Adrenergic beta-Antagonists; Carteolol; Drug Evaluation; Glaucoma; Humans; Intraocular Pressure; Met | 1988 |